TW202210504A - 對抗sars相關冠狀病毒之中和抗體 - Google Patents

對抗sars相關冠狀病毒之中和抗體 Download PDF

Info

Publication number
TW202210504A
TW202210504A TW110119505A TW110119505A TW202210504A TW 202210504 A TW202210504 A TW 202210504A TW 110119505 A TW110119505 A TW 110119505A TW 110119505 A TW110119505 A TW 110119505A TW 202210504 A TW202210504 A TW 202210504A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
variable region
chain amino
Prior art date
Application number
TW110119505A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬 貝克
亨寧 格魯爾
弗洛里安 克萊因
克里斯托夫 克里爾
馬蒂亞斯 策納
Original Assignee
德國科隆大學
德國馬爾堡菲利普大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德國科隆大學, 德國馬爾堡菲利普大學 filed Critical 德國科隆大學
Publication of TW202210504A publication Critical patent/TW202210504A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW110119505A 2020-05-29 2021-05-28 對抗sars相關冠狀病毒之中和抗體 TW202210504A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20177354.6 2020-05-29
EP20177354 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562.0 2020-12-11
EP20213562 2020-12-11

Publications (1)

Publication Number Publication Date
TW202210504A true TW202210504A (zh) 2022-03-16

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110119505A TW202210504A (zh) 2020-05-29 2021-05-28 對抗sars相關冠狀病毒之中和抗體

Country Status (6)

Country Link
US (1) US20210371503A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023528826A (cg-RX-API-DMAC7.html)
CA (1) CA3180556A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210504A (cg-RX-API-DMAC7.html)
WO (1) WO2021239935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.

Also Published As

Publication number Publication date
WO2021239935A9 (en) 2023-07-13
EP4157455A1 (en) 2023-04-05
US20210371503A1 (en) 2021-12-02
JP2023528826A (ja) 2023-07-06
CA3180556A1 (en) 2021-12-02
WO2021239935A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
US20210371503A1 (en) Neutralizing antibodies against sars-related coronavirus
JP7498714B2 (ja) B型肝炎ウイルスを中和する抗体およびその使用
JP2023525039A (ja) Sars-cov-2に対する抗体
JP2023523549A (ja) SARS-CoV-2に対する抗体およびそれを使用する方法
US20210079069A1 (en) Neutralizing anti-influenza binding molecules and uses thereof
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
JP2024527607A (ja) 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
US20210244825A1 (en) Il-21 antibodies
WO2021218879A1 (zh) Sars-cov-2中和抗体及其制备和应用
JP2023550785A (ja) 複数のベータコロナウイルスに結合する抗体
TW202144406A (zh) SARS-CoV-2抗體及其應用
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
TW202440626A (zh) Sars-cov-2中和抗體
JP2012510802A (ja) 完全ヒトインフルエンザm2特異的抗体
JP2025526405A (ja) Rsv及びmpvパラミクソウイルスに対する広域中和抗体
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
TW202411247A (zh) 針對流感神經胺酸酶的廣泛中和抗體
WO2023230448A1 (en) Combination immunotherapy for influenza
CN114761428B (zh) 抗血凝素抗体及其使用方法
JP2024533166A (ja) 小児被験体におけるSARS-CoV-2感染の抗体療法
WO2023288078A1 (en) Coronavirus antibodies and uses thereof
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法